Allopurinol hypersensitivity reactions: Desensitization strategies and new therapeutic alternative molecules

Inflammation and Allergy - Drug Targets

Volumn 12, Issue 1, 2013, Pages 19-28

  Calogiuri, Gianfranco ^a,b   Nettis, Eustachio ^b   Di Leo, Elisabetta ^b   Foti, Caterina ^b   Ferrannini, Antonio ^b   Butani, Lavjay ^c  

^a Pneumology Department   (Italy)

^b UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Allopurinol; Anakinra; Desensitization; Febuxostat; Hypersensitivity; Rasburicase

Indexed keywords

ALLOPURINOL; BENZBROMARONE; CLOPIDOGREL; COLCHICINE; COTRIMOXAZOLE; ETANERCEPT; FEBUXOSTAT; IMMUNOGLOBULIN E; INFLIXIMAB; INTERLEUKIN 1; MACROGOL; METHYLPREDNISOLONE; PEGLOTICASE; PIPERAZINE CITRATE; PREDNISONE; PROBENECID; RASBURICASE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RECOMBINANT URATE OXIDASE; SULFINPYRAZONE; TUMOR NECROSIS FACTOR ALPHA; URICOSURIC AGENT;

ACUTE KIDNEY FAILURE; ANAPHYLAXIS; ARTICLE; DISEASE EXACERBATION; DOSAGE SCHEDULE COMPARISON; DRESS SYNDROME; DRUG DESENSITIZATION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHEMA; FATIGUE; GOUT; HEMOLYSIS; HEPATITIS; HUMAN; HYPERURICEMIA; IMMUNOLOGICAL TOLERANCE; INFLAMMATION; LOW DRUG DOSE; MOUTH ULCER; PAIN; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RECOMMENDED DRUG DOSE; RESPIRATORY DISTRESS; SACCHAROMYCES CEREVISIAE; SKIN MANIFESTATION; STEVENS JOHNSON SYNDROME; STRIDOR; SUSPENSION; SWELLING; TOXIC EPIDERMAL NECROLYSIS; TUMOR LYSIS SYNDROME; URIC ACID BLOOD LEVEL;

ALLOPURINOL; ANIMALS; DESENSITIZATION, IMMUNOLOGIC; DRUG HYPERSENSITIVITY; GOUT; HUMANS; HYPERURICEMIA; PRODUCT SURVEILLANCE, POSTMARKETING; RECOMBINANT PROTEINS; SKIN; THIAZOLES; URATE OXIDASE;

EID: 84875951584     PISSN: 18715281     EISSN: None     Source Type: Journal    
DOI: 10.2174/1871528111312010004     Document Type: Article

References (67)

1. Rundles, R.W. The development of allopurinol. Arch. Intern. Med., 1985, 145, 1492-1503.
2. McInnes, G.T.; Lawson, D.H.; Jick H. Acute adverse reactions attributed to allopurinol in hospitalized patients. Ann. Rheum. Dis., 1981, 40, 245-249.
3. Gutiérrez-Macías A.; Lizarralde-Palacios E.; Martínez-Odriozola P.; Miguel-De la Villa F. Fatal allopurinol hypersensitivity syndrome after treatment of asymptomatic hyperuricemia. B.M.J., 2005, 331, 623-624.
4. Saxeena R.; Loghmanee F. Fatal drug eaction due to allopurinol therapy in a 72 year old man. Arch. Pathol. Lab. Med., 2005, 129, e183-e184.
5. Singer J.Z.; Wallace S.L. The allopurinol hypersensitivity syndrome. Unnecessary morbidity and mortality. Arthritis Rheum. 1986, 29, 82-87.
6. Emmerson B.T.; Hazel R.A.; Frazer I.H. Some adverse reactions to allopurinol may be mediated by lymphocyte reactivity to oxypurinol. Arthritis Rheum., 1988, 31, 436-440.
7. Hung, S.L.; Chung W.H.; Liou L.B.; Chu C.C.; Lin, M.; Huang, H.P.; Lin, Y.L.; Lan, J.L.; Yang, L.C.; Hong, H.S.; Chen, M.J.; Lai, P.C.; Wu, M.S.; Chu, C.Y.; Wang, K.H.; Chen, C.H.; Fann, C.S.; Wu, J.Y.; Chen, Y.T. HLAB* 5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. P.N.A.S., 2005, 102, 4134-4139.
8. Halevy S.; Ghislain P.D.; Mockenhaupt M.; Fagot J.P.; Bouwes Bavinck J.N.; Sidoroff A.; Naldi L.; Dunant A.; Viboud C.; Roujeau J.C. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J. Am. Acad. Dermatol. 2008, 58, 25-32.
9. Braden G.L.; Warzynski M.J.; Golightly M.; Ballow M. Cell mediated immunity in allopurinol induced hypersensitivity. Clin. Immunol. Immunopathol.,1994, 70, 145-151.
10. Utsinger P.D.; Young W.J. Allopurinol hypersensitivity. Granular deposition of IgM at the dermal-epidermal junction. Am. J. Med., 1976, 61, 287-294.
11. Gruchalla R.S. Acute drug desensitization. Clin. Exp. Allergy, 1998, 28 (Suppl. 4), 63-74.
12. Solenky R. Drug desensitization. Immunol. Allergy Clin. North Am., 2004, 24, 425-433.
13. Teraki Y.; Shiohara T. Successful desensitization to fixed drug eruption: the presence of CD25+CD4+ T cells in the epidermis of fixed drug eruption lesions may be involved in the induction of desensitization. Dermatology, 2004, 209, 29-32.
14. Kelso J.M.; Keating R.M. Successful desensitization for treatment of a fixed drug eruption to allopurinol. J. Allegy Clin. Immunol., 1996, 97, 1171-1172.
15. Umpierrez A.; Herranz J.C.; De Las Heras M.; Lluch-Bernal M.; Figueredo E.; Sastre J. Successful desensitization of a fixed drug eruption caused by allopurinol. J. Allergy Clin. Immunol., 1998, 101, 286-287
16. Meyrier A. Desensitization in a patient with chronic renal disease and severe allergy to allopurinol. B.M.J., 1976, 2 (6033), 458.
17. Webster E.; Panush R.S. Allopurinol hypersensitivity in a patient with severe chronic tophaceous gout. Arthritis Rheum. 1985, 28, 707-709.
18. Fam A.G.; Lewtas J.; Stein J.; Paton T.W. Desensitization to allopurinol in patients with gout and cutaneous reactions. Am. J. Med., 1992, 93, 299-302.
19. Fam A.G.; Dunne S.M.; Iazette J.; Paton T.W. Efficacy and safety of desensitization to allopurinol following cutaneous reactions. Arthritis Rheum., 2001, 44, 231-238.
20. Gillott T.J.; Whallett A.; Zaphiropoulos G. Oral desensitization in patients with chronic tophaceous gout and allopurinol hypersensitivity. Rheumatology, 1999, 38, 85-86.
21. Melson R.D. Familial hypersensitivity to allopurinol with subsequent desensitization. Rheumatology, 1999, 38, 1301
22. Unsworth J.; Blake D.T.; D'Assa Fonseca A.E.; Beswick D.T. Desensitization to allopurinol: a cautionary tale. Ann. Rheum. Dis., 1987, 46, 646.
23. Tanna S.B.; Barnes J.F.; Seth S.K. Desensitization to allopurinol in a patient with previous failed desensitization. Ann. Pharmacother., 1999, 33, 1180-1183.
24. Nitti F.; Fumagalli M.; Incorvaia C. Rush desensitization to allopurinol. Allergy, 2003, 58, 690.
25. McDonald J.; Fam A.G.; Paton T.; Senn J. Allopurinol hypersensitivity in a patient with coexistent systemic lupus erythematosus and tophaceous gout. J. Rheumatol., 1988, 15, 865-868.
26. Waltz-LeBlanc B.A.; Reynolds W.J.; McFadden D.K. Allopurinol sensitivity in a patient with chronic tophaceous gout: success of intravenous desensitization after failure of oral desensitization. Arthritis Rheum., 1991, 34, 1329-1331.
27. Schumacher M.J.; Copeland J.G. Intravenous desensitization to allopurinol in a heart transplant patient with gout. Ann. Allergy Asthma Immunol., 2004, 92, 374-376.
28. Douglas R.; Spelman D.; Czarny D.; O'Hehir R.E. Successful desensitization of two patients who previously developed Stevens Johnson syndrome while receiving trimethoprim-sulfamethoxazole. Clin. Infect. Dis., 1997, 25, 1480.
29. Ruano F.J.; Garcimartin M.I.; Vazquez de la Torre M.; Blanca M.; Canto G. Desensitization to epoetin alpha in a confirmed case of acute exanthematic pustolosis. Allergy, 2009, 64, 1797-1798.
30. Ellerbroek J.C.; Cleveland M.G. Clopidogrel associated acute generalized exanthematous pustolosis. Cutis, 2011, 87, 151-155
31. Vaquez-Mellado J.; Vaquez S.G.; Barrientos J. C,; Rios V. G,; Burgos-Vargas R. Desensitization to allopurinol after allopurinol hypersensitivity syndrome with renal involvement in gout. J. Clin. Rheumatol., 2000, 6(5), 266-268.
32. Ooi C.G.; Walker P.; Sidhu S.K.; Gordon L.A.; Mardhman G. Allopurinol induced generalized eosinophilic pustular folliculitis. Austral. J. Dermatol., 2006, 47, 270-273.
33. Maejima H.; Mukai H.; Hikaru E. Eosinophilic pustular folliculitis induced by allopurinol and timepidium bromide. Acta Dermatol. Venereol., 2002, 82, 316-317.
34. Duchene D.A.; Smith C.P.; Goldfarb R.A. Allopurinol induced meningitis. J. Urol., 2000, 164, 2028.
35. Greenberg L.E.; Nguyen T.; Miller S.M. Suspected allopurinol induced aseptic meningitis. Pharmacotherapy, 2001, 21, 1007-1009.
36. Chao S.C.; Yang C.C.; Lee J.Y. Hypersensitivity syndrome and pure red cell aplasia following allopurinol therapy in a patient with chronic kidney disease. Ann. Pharmacother., 2006, 39, 1552-1556.
37. Bardin T. Current management of gout in patients unresponsive or allergic to allopurinol. Joint Bone Spine, 2004, 71, 481-485.
38. Jansen T.L.; Reinders M.K.; van Roon E. N Benzbromarone withdrawn from the European market: another case of "absence of evidence is evidence of absence"? Clin. Exp. Rheumatol., 2004, 22(5), 651.
39. Cammalleri L.; Malaguarnera L. Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout. Int. J. Med. Sci., 2007, 4, 83-93.
40. Yim B.T.; Sims-McCallum R.P.; Chomg P.H. Rasburicase for the treatment and prevention of hyperuricemia. Ann. Pharmacother., 2003, 37, 1047-1054.
41. Vogt B. Urate oxidase (rasburicase) for treatment of severe tophaceous gout. Nephrol. Dial. Transplant, 2005, 20, 431-433.
42. Moolenburgh J.D.; Reinders M.K.; Jansen T.L. Rasburicase treatment in severe tophaceous gout: a novel therapeutic option. Clin. Rheumatol., 2006, 25, 749-752.
43. Richette P.; Bardin T. Successful treatment with rasburicase of a tophaceous gout in a patient allergic to allopurinol. Nat. Clin. Pract. Rheumatol., 2006, 2, 338-342.
44. Wipfler-Freibmuth E.; Dejaco C.; Duftner C.; Gaugg M.; Kriessmayr-Lungkofler M.; Schirmer M. Urate oxidase (rasburicase) for treatment of severe acute gout: a case report. Clin. Exp. Rheumatol., 2009, 27, 658-660.
45. Bomalaski J.S.; Clark M.A. Serum acid lowering therapies: where are we heading in managment of hyperuricemia and the potential role of uricase. Curr. Rheum. Reports, 2004, 6, 240-247.
46. Trujillo M.; Morales M. Rasburicase induced fatal respiratory arrest? Ann. Oncol., 2007, 18, 399-400.
47. Chou H.; Lin W.L.; Tam M.F.; Wang S.R.; Han S.H.; Shen H.D. Alkaline serine proteinase is a major allergen of Aspergillus flavus, a prevalent airborne aspergillus species in the Taipei area. Int. Arch. Allergy Immunol., 1999, 119, 282-290.
48. Richette P.; Briere C.; Hoenen-Clavert V.; Loeuille D.; Bardin T. Rasburicase for tophaceous gout not treatable with allopurinol: an exploratory study. J. Rheumatol., 2007, 34, 2093-2098.
49. Hill C.L.; Lu T.Y.; Cervelli M.; Mathew T. Failure of rasburicase therapy in recurrent acute gout with tophi. Int. J. Rheum. Dis., 2008, 11, 315-317.
50. Sherman M.R.; Saifer M.G.P.; Perez-Ruiz F. PEG-uricase in the management of treatment-resistant gout and hyperuricemia. Adv. Drug Deliv. Rev., 2008, 60, 59-68
51. Busso N.; So A. Mechanism of inflammation in gout. Arthr. Res. Ther., 2010, 12, 206.
52. Tausche A.K.; Richter K.; Grassler A.; Hansel S.; Roch B.; Schroder H.E. Severe gouty arthritis refractory to antiinflammatory drugs: treatment with anti-tumor necrosis factor alpha as a new therapeutic option. Ann. Rheum. Dis., 2004, 63, 1351-1352.
53. Fiehn C.; Zeier M.; Fiehn C.; Zeier M. Successful treatment of chronic tophaceous gout with infliximab (Remicade). Rheumatol. Int., 2006, 26, 274-276.
54. McGonagle D.; Tan A.L.; Shankaranamrayana S., Madden J., Emery P., McDermott M.F. Management of treatment resistant inflammation of acute on chronic tophaceous gout with anakinra. Ann. Rheum., 2007, 66, 1683-1684.
55. Gratton S.B.; Scalapino K.J.; Fye K.H. Case of anakinra as a steroid-sparing agent for gout inflammation. Arthritis Rheum., 2009, 61, 1268-1270.
56. So A.; de Smedt T.; Revaz S.; Tschopp J. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res. Ther., 2007, 9(2), R28.
57. Chen K.; Fields T.; Mancuso C.A.; Bass A.R.; Vasanth L. Anakinra's efficacy is variable in refractory gout: report of ten cases. Semin. Arthritis Rheum., 2010, 40, 210-214.
58. Reinders M.K.; van Roon E.N.; Brouwers J.R.; Jansen T.L. A costly therapeutic dilemma in tophaceous gout: is etanercept or rasburicase preferable? Ann. Rheum. Dis., 2005, 64, 516.
59. Yu KH. Febuxostat: a novel non-purine selective inhibitor of xanthine oxidase for the treatment of hyperuricemia in gout. Recent Pat. Inflamm. Allergy Drug Discov., 2007, 1, 69-75.
60. Becker M.A.; Schumacher R.; Wortmann R.L.; MacDonald, P.A.; Eustace, D.; Palo, W.A.; Streit, J.; Joseph-Ridge, N. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N. Engl. J. Med., 2005, 353, 2450-2461.
61. Dubchak N.; Falasca G. New and inmproved strategies for the treatment of gout. Int. J. Nephrol. Renovascul. Dis., 2010, 3, 145-166
62. Chohan S. Safety and efficacy of febuxostat treatment in subjects with gout and severe allopurinol adverse reactions. J Rheumatol., 2011, 38, 1957-1959.
63. Otto A. Febuxostat tied to hypersensitivity reactions. http://fpn.imng.com/fileadmin/content_pdf/fpn/archive_pdf/vol40is s11/70717_main.pdf.
64. Abeles A.M. Febuxostat hypersensitivity. J. Rheumatol., 2012, 39, 3.
65. Sullivan T. Protocols for Rapid and Slow Drug Allergy Desensitization. pg 32. First Edition, November 2009. http://www.scribd.com/doc/22062135/Protocols-for-Drug-Allergy-Desensitization
66. Cernadas J.R.; Brockow K.; Romano A.; Aberer W. Torres, M.J.; Bircher, A.; Campi, P.; Sanz, M.L.; Castells, M.; Demoly, P.; Pichler, W.J.; European Network of Drug Allergy and the EAACI interest group on drug hypersensitivity. General considerations on rapid desensitization for drug hypersensitivity-a consensus statement. Allergy, 2010, 65, 1357-1366.
67. Calogiuri G.; Satriano F.; Muratore L.; Valacca A.; Nettis E.; Di Leo E.; Vacca A. Therapeutic alternatives in a patient with DRESS syndrome induced by allopurinol.J. Invest. Allergol. Clin. Immunol., 2009, 19, 333-334.